Sidney Farber and the Treatment of Childhood Acute Lymphoblastic Leukemia with a Chemotherapeutic Agent

  title={Sidney Farber and the Treatment of Childhood Acute Lymphoblastic Leukemia with a Chemotherapeutic Agent},
  author={Domenico Ribatti},
  journal={Pediatric Hematology and Oncology},
  pages={299 - 302}
  • D. Ribatti
  • Published 27 April 2012
  • Medicine
  • Pediatric Hematology and Oncology
Acute lymphoblastic leukemia (ALL) is the most common malignancy affecting children accounting for approximately 30% of childhood cancers, which was uniformly fatal before the advent of effective chemotherapy. In this historical note, the fundamental contribution of Sidney Farber to the treatment of ALL by using, for the first time, aminopterin—a chemotherapeutic agent—has been recognized. 
Advent of CRISPR Based Immunotherapy in Hematologic Malignancies
While the development of chemotherapeutics for hematologic cancers has advanced tremendously, much progress remains, one area in which the frontier of cancer treatment is being pushed is in multiple myeloma.
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
This work builds on a compendium of resistant mutations to small molecule inhibitors reported in the literature and provides a comprehensive review ofresistant mutations in cancers, and discusses mechanistic parallels of resistance.
The mechanism of action of iminosugars as antiretrovirals
It is demonstrated that, at antiviral concentrations, only a small proportion of viral glycoproteins are misfolded suggesting an amplification effect from protomer oligomerisation and clustering, and confirmed that failure to process glycans beyond glucose trimming can be substantially antiviral in at least one HIV isolate.
Quality and safety in pediatric hematology/oncology
This review explores why specialists in pediatric hematology/oncology should be leaders in the field of quality and safety in healthcare.
The Clinical Translation Gap in Child Health Exercise Research: A Call for Disruptive Innovation
This report presents specific plans to bolster data interoperability, improve child health CPET reference values, stimulate formal training in exercise medicine for child health care professionals, and outline innovative approaches through which exercise medicine can become more accessible and advance therapeutics across the broad spectrum of child health.
  • 2014


Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid.
The occurrence of what the author interpreted as an "acceleration phenomenon" in the leukemic process as seen in the marrow and viscera of children with acute leukemia treated by the injection of folic acid conjugates1 and pteroyltriglutamic acid (teropterin) — and an experience gained from studies on folic .
Acute lymphoblastic leukemia in children: current status, controversies, and future perspective.
Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer.
No evidence has been presented which would justify the use of the word "cure" of acute leukemia, and two of the most pressing problems demanding solution are concerned with the nature, the prevention, and the treatment of toxic changes, including hemorrhage, produced by these folic acid antagonists.
Factors influencing the specificity of action of an antileukemic agent (aminopterin); time of treatment and dosage schedule.
Summary The antileukemic specificity of action of aminopterin, defined in terms of the relative effect of drug on host and tumor, was demonstrated to vary with the time of treatment following tumor
Nitrogen mustard therapy; studies on the effect of methyl-bis (beta-chloroethyl) amine hydrochloride on neoplastic diseases and allied disorders of the hemopoietic system.
A clinical investigation was initiated on patients with neoplastic diseases of the hemopoietic system on whom prolonged observation as to the therapeutic efficacy of the drug could be made of tris(β-chloroethyl) amine hydrochloride.
Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders.
The present preliminary communication concerns the clinical use of halogenated alkyl amines in the treatment of lymphosarcoma, Hodgkin's disease, leukemia and a limited number of allied and miscellaneous disorders.
Disaster at Bari
Pteroylaspartic acid, an antagonist for pteroylglutamic acid.
Weisses blut.
  • C. Grant
  • Medicine
    Radiologic technology
  • 2002
Acute lymphoblastic leukemia.